関連する実験動画
Updated: Aug 28, 2025
05:53
Use of a Hanging-weight System for Liver Ischemia in Mice
Published on: August 7, 2012
16.1K
凝固因子XIによる肝心クロストークは,心不全から保護します
Yang Cao1, Yuchen Wang1, Zhenqi Zhou2
1Department of Medicine, Division of Cardiology, University of California, Los Angeles, CA 90095, USA.
Science (New York, N.Y.)
|September 22, 2022
まとめ
血液凝固因子XI (FXI) は肝臓のタンパク質で,骨形態遺伝タンパク質 (BMP) 経路を活性化することによって,心臓を腹動機能障害から保護する. この新しい発見は,FXI
科学分野:
- 心血管生物学
- 内分泌学
- システム遺伝学
背景:
- 内分泌因子は生理学的恒常性のために不可欠な組織間のコミュニケーションを媒介する.
- 放出分数保存 (HFpEF) による心不全は,静脈動脈機能不全によって特徴づけられる.
- 心臓機能における凝固因子XI (FXI) の役割はほとんど研究されていない.
研究 の 目的:
- 凝固因子XI (FXI) の潜在的心臓保護作用を調査する.
- 心臓機能に対するFXIの作用の基礎となる分子メカニズムを解明する.
主な方法:
- 様々なマウス株からのトランスクリプトミックおよび機能データのシステム遺伝学分析.
- マウスでの機能増減の研究
- 心臓組織における骨形態遺伝タンパク質 (BMP) - SMAD1/5信号経路の活性化に関する分析
- 細胞外マトリックス関連BMP7に対するFXIのタンパク質分解作用の評価
主要な成果:
- システム遺伝学では FXIは 腹筋機能不全から守ると予測されています
- 機能の獲得と喪失の研究は,心臓におけるFXIの保護的役割を確認した.
- FXIは心臓のBMP-SMAD1/5経路を活性化する.
- FXIのタンパク質分解作用は,BMP7の分裂と活性化に不可欠であり,心臓の炎症と線維症を抑制します.
結論:
- FXIは,凝固機能とは独立して,心臓の損傷に対する保護的役割を果たします.
- 心臓のBMP- SMAD1/5経路のFXIの活性化は炎症と線維症を緩和する.
- この研究は,心血管の健康におけるFXIの新しい非静止機能を明らかにした.
関連する概念動画
01:29Heart Failure II: Pathophysiology
31
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
31
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
857
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
857
01:17Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
01:22Heart Failure VI: Adjunct Therapies
25
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25
01:20Extrinsic and Intrinsic Pathways of Hemostasis
9.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.0K
01:09Coagulation
7.3K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.3K